Skip to main content

Table 1 Baseline characteristics of participants by quartiles of SII

From: The association between systemic immune-inflammation index and in vitro fertilization outcomes in women with polycystic ovary syndrome: a cohort study

Characteristics

Quantile 1 (N = 242)

Quantile 2 (N = 241)

Quantile 3 (N = 241)

Quantile 4 (N = 242)

P-value

Age

28.32 ± 3.18

28.54 ± 3.23

28.20 ± 3.33

28.18 ± 2.92

0.581

Primary infertility

164 (67.8%)

173 (71.8%)

183 (75.9%)

176 (72.7%)

0.254

 

78 (32.2%)

68 (28.2%)

58 (24.1%)

66 (27.3%)

 

Duration of infertility(y)

3.12 ± 2.00

3.37 ± 1.96

3.21 ± 2.04

3.45 ± 2.19

0.281

Smoking history, n (%)

 No

240 (99.2%)

240 (99.6%)

240 (99.6%)

240 (99.2%)

1.000

 Yes

2 (0.8%)

1 (0.4%)

1 (0.4%)

2 (0.8%)

Gravidity

0.00 (0.00 to 1.00)

0.00 (0.00 to 1.00)

0.00 (0.00 to 1.00)

0.00 (0.00 to 1.00)

0.363

Parity

0.00 (0.00 to 0.00)

0.00 (0.00 to 0.00)

0.00 (0.00 to 0.00)

0.00 (0.00 to 0.00)

0.662

Number of abortions

0.00 (0.00 to 1.00)

0.00 (0.00 to 0.00)

0.00 (0.00 to 0.00)

0.00 (0.00 to 0.00)

0.661

Basal FSH(IU/L)

6.84 ± 1.58

6.74 ± 3.03

6.60 ± 1.39

6.37 ± 1.65

0.060

Basal E2(pg/mL)

55.11 ± 10.20

44.41 ± 20.33

50.26 ± 37.80

46.47 ± 20.89

0.182

Basal LH(IU/L)

7.72 ± 4.01

7.11 ± 4.02

7.71 ± 4.02

7.98 ± 4.69

0.139

Basla T(ng/dl)

0.56 (0.43 to 0.70)

0.55 (0.43 to 0.72)

0.56 (0.42 to 0.70)

0.57 (0.42 to 0.75)

0.997

AMH (ng/ml)

11.16 ± 5.28

11.48 ± 5.48

11.52 ± 5.32

12.27 ± 5.67

0.155

AFC

14.23 ± 4.27

15.07 ± 4.79

16.16 ± 5.28

16.46 ± 5.17

 < .001

BMI (Kg/m2)

    

0.680

  < 18.5

11 (4.55%)

8 (3.32%)

8 (3.32%)

11 (4.55%)

 

 18.5–25

144 (59.50%)

128 (53.11%)

143 (59.34%)

132 (54.55%)

 

 25–30

65 (26.86%)

77 (31.95%)

71 (29.46%)

69 (28.51%)

 

  ≥ 30

22 (9.09%)

28 (11.62%)

19 (7.88%)

30 (12.40%)

 

Starting dose of Gn (IU)

188.21 ± 33.11

192.71 ± 39.46

188.68 ± 35.15

188.42 ± 36.61

0.466

Total Gn dose (IU)

1834.29 ± 590.33

1887.87 ± 659.64

1852.45 ± 712.67

1795.18 ± 625.93

0.464

Duration of Gn (day)

9.29 ± 1.72

9.24 ± 1.72

9.28 ± 2.01

9.18 ± 1.48

0.910

Starting dose of GnRH-ant (IU)

0.25 (0.12 to 0.25)

0.25 (0.12 to 0.25)

0.25 (0.12 to 0.25)

0.25 (0.12 to 0.25)

0.258

Total GnRH-ant dosea(IU)

1.12 (0.75 to 1.50)

1.00 (0.75 to 1.50)

1.25 (0.88 to 1.50)

1.25 (0.88 to 1.50)

0.155

Duration of GnRH-ant (day)

5.19 ± 2.16

4.82 ± 1.75

5.10 ± 1.87

5.17 ± 1.82

0.121

Triggered with hCG

217(89.67%)

209(86.72%)

206(85.48%)

197(81.40%)

0.072

Triggered with GnRH-a + HCG

25(10.33%)

32(13.28%)

35(14.52%)

45(18.59%)

 

E2 on HCG start day (pg/ml)

5769.50 (4257.00 to 8217.00)

5612.00 (4395.00 to 8325.00)

6142.00 (4555.00 to 9117.00)

6871.00 (4805.37 to 9928.00)

0.019

P on HCG start day(ng/ml)

1.25 (0.91 to 1.69)

1.29 (0.94 to 1.70)

1.31 (0.92 to 1.84)

1.42 (1.05 to 2.00)

0.017

LH on HCG start day (IU/L)

2.69 (1.67 to 3.97)

2.65 (1.66 to 3.96)

2.67 (1.75 to 4.77)

2.59 (1.64 to 4.64)

0.907

P on HCG start day(ng/ml)

1.25 (0.91 to 1.69)

1.29 (0.94 to 1.70)

1.31 (0.92 to 1.84)

1.42 (1.05 to 2.00)

0.017

LH on HCG start day (IU/L)

2.69 (1.67 to 3.97)

2.65 (1.66 to 3.96)

2.67 (1.75 to 4.77)

2.59 (1.64 to 4.64)

0.907

  1. Data are expressed as median (interquartile range) for non-normally distributed continuous variables
  2. Data are expressed as mean + SD for normally distributed continuous variables
  3. Categorical variables were expressed in frequency or as a percentage
  4. Abbreviations: SII Systemic immune-inflammation index, BMI Body mass index, FSH Follicle-stimulating hormone, LH Luteinizing hormone, T Testosterone, AMH Anti-müllerian hormone, P Progesterone, AFC Antral follicle count, Gn Gonadotropin, GnRH-ant Gonadotropin releasing hormone antagonist, HCG Human chorionic gonadotropin, GnRH-a Gonadotropin releasing hormone agonist